Staff profile

Dr Joanne Casey

Research Fellow

Faculty of Science, Technology and Engineering

School of Molecular Sciences
Department of Biochemistry

Melbourne (Bundoora)

 

Qualifications

BSc(Hons) (Sheffield,UK), PhD (London,UK)

Area of study

Biochemistry and Molecular Biology

Brief Profile

I am currently employed by the CRC for Biomarker Translation as a postdoctoral fellow to identify novel high affinity reagents against a range of commercially important target molecules.

Recent Publications

 

1.    Griffiths K, Dolezal O, Parisi K, Angerosa J, Dogovski C, Barraclough M, Sanalla A, CASEY JL, Gonzalez I, Perugini MA, Nuttall S, Foley M. (2013) Shark variable new antigen receptor (VNar) single domain antibody fragments: Stability and disgnostic applications. Antibodies. 2: 66-81.

2.    Siddiqui AA, Xainli J, Schloegel J, Carias L, Ntumngia F, Shoham M, CASEY JL, Foley M, Adams JH, King CL. (2012) Fine specificity of Plasmodium vivax duffy binding protein binding engagement of the duffy antigen on human erythrocytes. Infect. Immun. 80 (8) 2920-2928.

3.    CASEY JL, Sanalla AM, Tamvakis D, Thalmann C, Carroll EL, Parisi K, Coley AM, Stewart DJ, Vaughan JA, Michalski WP, Luke R, Foley M. (2011) Peptides specific for Mycobacterium avium subspecies paratuberculosis infection: diagnostic potential. Protein Eng Des Sel. 24 (8), 589-596.

4.    Harris KS, CASEY JL, Coley AM, Karas JA, Sabo JK, Tan YY, Dolezal O, Norton RS, Hughes AB, Scanlon D, Foley M. (2009) Rapid optimization of a peptide inhibitor of malaria parasite invasion by comprehensive N-methyl scanning. J Biol Chem. 284 (14) 9361-71.

5.    Read AJ, CASEY JL, Coley AM, Foley M, Gauci CG, Jackson DC, Lightowlers MW. (2009) Isolation of antibodies specific to a single conformation-dependant antigenic determinant on the EG95 hydatid vaccine. Vaccine. 27 (7), 1024-31.

6.    CASEY JL, Coley AM, Parisi K, Foley M. (2008) Peptide mimics selected from immune sera using phage display technology can replace native antigens in the diagnosis of Epstein-Barr virus infection. Protein Eng Des Sel. 22(2), 85-91.

7.      CASEY JL, Coley AM, Foley M. (2008) Phage display of peptides in ligand selection for use in affinity chromatography. Methods Mol Biol. 421:111-24.

8.    Tschiggerl H, CASEY JL, Parisi K, Foley M, Sleytr UB. (2008) Display of a peptide mimotope on a crystalline bacterial cell surface layer (S-layer) lattice for diagnosis of Epstein-Barr virus infection. Bioconjugate Chem. 19, 860-65.

9.    Sabo JK, Keizer DW, Feng ZP, CASEY JL, Parisi K, Coley AM, Foley M, Norton RS. (2006) Mimotopes of apical membrane antigen 1:structures of phage derived peptides recognised by the inhibitory monoclonal antibody 4G2dc1 and design of a more active analogue. Infect. Immun. 75 (1):61-73.

10. Coley AM, Parisi K, Masciantonio R, Hoeck J, CASEY JL, Murphy VJ, Harris KS, Batchelor AH, Anders AH, Anders RF, Foley M. (2006) The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion inhibitory antibody. Infect. Immun. 74 (5):2628-2636.

11. CASEY JL, Coley AM, Street G, Parisi K, Devine PL, Foley M. (2006) Peptide mimotopes selected from a random peptide library for diagnosis of Epstein-Barr virus infection. J. Clin. Micro. 44 (3):764-771.

12. Harris KS, CASEY JL, Coley AM, Masciantonio R, Sabo JK, Keizer DW, Lee EF, McMahon A, Norton RS, Anders RF, Foley M. (2005) Binding hot spot for invasion inhibitory molecules on Plasmodium falciparum Apical membrane antigen 1. Infect. Immun. 73 (10):6981-6989.

13. CASEY JL, Coley AM, Anders RF, Murphy VJ, Humberstone KS, Thomas AW, Foley M. (2004) Antibodies to Malaria Peptide Mimics Inhibit Plasmodium falciparum Invasion of Erythrocytes. Infect. Immun. 72 (2):1117-1125.

14. Nuttall SD, Humberstone KS, Krishnan UV, Carmichael JA, Doughty L, Hattarki M, Coley AM, CASEY JL, Anders RF, Foley M, Irving RA, Hudson PJ. (2004) Selection and affinity maturation of IgNAR variable domains targeting plasmodium falciparum AMA1. Proteins 55:187-197.

15. CASEY JL, Coley AM. (2003) Cambridge Healthtech Instsitutes 4th Annual Recombinant Antibodies conference. Expert Opin. Biol. Ther. 3 (5):859-862.

16. Coley AM, CASEY JL. (2003) Cambridge Healthtech Institutes 5th Annual Molecular display the chemistry set for proteins and small molecules conference. Expert Opin. Biol. Ther. 3 (5):855-858.

17. CASEY JL, Napier MP, King DJ, Chaplin LC, Weir N, Green AJ, Hope-Stone LD, Yarranton GT, Begent RHJ.  (2002) Tumour targeting of humanized cross-linked divalent-fab’ antibody fragments: a clinical phase I/II study. Br. J. Cancer  86: 1401-1410.

18. Coley AM, Campanali NV, CASEY JL, Anders R, Tilley LM, Foley M. (2001) Rapid and precise epitope mapping of AMA-1 specific monoclonal antibodies. Protein Engineering  14 (9): 691-698.

19. Verhaar-Langereis MJ, Eagle KF, Keep PA, CASEY JL, Begent RHJ. (2000) Anaphylactic reaction to radioimmunotherapy despite plasmapheresis to remove anti-mouse antibodies. J R Soc Med. 93 (2):75-6.

20. CASEY JL, Pedley RB, King DJ, Chapman A, Yarranton GT, Begent RHJ. (2000)  Improved tumour targeting of di-Fab' fragments modified with polyethylene glycol.  Tumour Targeting  4: 235-244.

21. CASEY JL, Coley AM, Tilley LM, Foley M. (2000) Green fluorescent antibodies: novel in vitro tools.  Protein Engineering  13 (6):445-452.

22. Klonis N, Wang H, Quazi N, CASEY JL, Deady L, Tilley LM.  (2000)  Perylene Diones: A new class of far-red fluorescent probes.  J. Fluorescence  11 (1):1-11.

23. CASEY JL, Pedley RB, King DJ, Green AJ, Yarranton GT, Begent RHJ. (1999) Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.  Br. J. Cancer  81 (6):972-80.

24. Flynn AA, Green AJ, Boxer GM, CASEY JL, Pedley RB, Begent RHJ.  (1999)  A novel technique using radioluminography for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model.  Int. J. Radiat. Oncol. Biol. Phys.  43 (1):183-189.

25. CASEY JL, King DJ, Pedley RB, Boden JA, Boden R, Chaplin LC, Dorning M, Begent RHJ. (1998)  Clearance of yttrium-90 labelled anti-tumour antibodies with antibodies raised against the 12N4 DOTA macrocycle.  Br. J. Cancer  78 (10):1307-1312.

26. Verhaar MJ, Hawkins RE, Robson L, CASEY JL, Pedley B, Boden JA, Begent RHJ, Chester KA. (1996)  Technetium-99m radiolabelling using a phage derived single chain Fv with a C-terminal cysteine.  J. Nucl. Med.  37 (5):868-872.

27. Begent RHJ, Verhaar MJ, Chester KA, CASEY JL, Green AJ, Napier MP, Hope-Stone LD, Cushen N, Keep PA, Johnson CJ, Hawkins RE, Hilson AJ, Robson L. (1996) Clinical evidence of efficient tumour targeting based on single chain Fv antibody selected from a combinatorial library.  Nature Medicine  2 (9):979-984.

28. CASEY JL, King DJ, Chaplin LC, Haines AM, Pedley RB, Mountain A, Yarranton GT, Begent RHJ. (1996)  Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments. Br. J. Cancer  74 (9):1397-1405.

29. CASEY JL, Keep PA, Chester KA, Robson L, Hawkins RE, Begent RHJ. (1995)  Purification of bacterially expressed single chain antibodies for clinical applications using metal chelate chromatography.  J. Immunol. Methods  179 (1):105-116.

30. Lane DM, Eagle KF, Begent RHJ, Hope-Stone LD, Green AJ, CASEY JL, Keep PA, Kelly AM, Ledermann JA, Glaser MG et al. (1994)  Radioimmunotherapy of metastatic colorectal tumours with Iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies.  Br. J. Cancer  70 (3):521-525.